1. Poland Stocks

  2. •

    Health technology

  3. •

    Medical specialties
MediNice SA

MediNice SA

GGPW:ICE
53.40
PLN
-0.40
(-0.74%)
-0.90EPS
684.43MMarket Cap
Nov 06Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.06
0.07
- -
0.04
0.07
0.05
0.04
0.04
0.03
- -
- -
Basic EPS, GAAP
-0.1
-0.15
-0.5
-0.56
-0.56
-0.5
-0.79
-0.79
5.62
-0.86
-0.9
Free Cash Flow per Basic Share
-0.19
-0.51
-0.57
-1.03
-1.16
-1.05
-1.01
-1.55
-1.59
-1.49
-1.19
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.05
0.98
0.87
1.88
3.17
6.54
5.92
5.13
10.57
9.67
9.08
Tangible Book Value per Share
-0.12
0.64
0.48
1
1.96
4.85
3.76
2.11
0.66
0.67
0.03
Basic Weighted Avg Shares
3
3
3
4
5
6
6
6
7
8
9
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-164.28
-254.3
-156,008.98
-1,357.93
-678.23
-1,152.63
-2,032.11
-2,568.44
-2,491.49
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-1
-2
-2
-3
-3
-5
-5
38
-7
-8
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-173.54
-208.69
-148,881.79
-1,498.17
-812.1
-1,012.63
-2,002.03
-2,254.22
19,987.77
- -
- -
Working Capital
1
3
1
6
12
32
21
10
7
9
3
LT Debt
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
3
3
8
17
41
37
33
81
88
84
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-29.69
-53.5
-44.29
-24.01
-10.04
-12.69
-14.43
65.82
-7.95
-9.75

Capital Structure

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
9
Market Capitalization
155
525
684

Working Capital

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
10
7
4
Cash, Cash Equivalents & STI
10
7
4
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
2
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

PLN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
54.52%
8.77%
Free Cash Flow
- -
15.07%
9.67%
Net Income, GAAP
- -
-177.92%
-117.89%
Sales/Revenue/Turnover
- -
-32.41%
-100%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.19
-0.18
-0.14
6.14
5.62
2025
-0.16
-0.2
-0.11
-0.4
-0.86
2026
-0.13
-0.28
- -
- -
- -

Quarterly Dividends Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sanjeev Choudhary
Full Time Employees
10
Sector
Health technology
Industry
Medical specialties
Address
Hankiewicza St. 2 Warsaw SK Poland 02-103
IPO Date
Sep 25, 2018
Website
medinice.pl
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Medinice S.A. is a medical technology firm specializing in innovative, minimally invasive solutions for the fields of cardiology and cardiac surgery. Established in Warsaw, Poland, in 2012, the company focuses on advancing concepts for medical devices that address crucial unmet needs in the market. Its portfolio includes a range of products designed to improve patient care, such as PacePress for reducing hematoma risk after CIED implantations, CoolCryo for efficient cardiac cryoablation, AtriClamp for left atrial appendage occlusion, and the MiniMax ablation catheter. The company actively supports the entire lifecycle of its medical innovations, from initial development and rigorous clinical trials to securing certifications and facilitating global market commercialization, often through licensing agreements. Recent strategic moves include receiving FDA feedback for its CoolCryo system and submitting it for cardiac cryoablation in 2025, alongside anticipating European market approval for its PacePress device. Furthermore, in September 2025, Medinice forged a letter of intent with U.S.-based CorNav Corporation to jointly develop and commercialize technologies for treating ventricular tachycardia, signaling a clear path for expansion into the American market.